Cannabidiol in epilepsy: The indications and beyond
Keyword(s):
Abstract Epilepsy, although common, remains difficult to treat with as much as 30% of patients having treatment-resistant conditions. Lennox-Gastaut syndrome and Dravet syndrome are childhood-onset epilepsies and among the most difficult to treat. Cannabidiol has been approved by the Food and Drug Administration to treat these conditions in individuals over 2 years of age; however, there is a great deal of interest in off-label use. This article examines 3 cases: 1 of a patient with Lennox-Gastaut syndrome, 1 of off-label use of cannabidiol to treat epilepsy, and 1 of nonprescription forms of cannabidiol to treat epilepsy.
2018 ◽
Vol 28
(3)
◽
pp. 216-224
◽
Keyword(s):
2008 ◽
Vol 19
(7)
◽
pp. 965-969
◽
Keyword(s):
2020 ◽
Vol 31
(4)
◽
pp. 622-628
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2019 ◽
Vol 215
(2)
◽
pp. 447-448
◽
2016 ◽
Vol 2
(1)
◽
Keyword(s):